Amalgamated Bank Has $30,000 Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM)

Amalgamated Bank lifted its stake in shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) by 97.3% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,768 shares of the company’s stock after acquiring an additional 872 shares during the quarter. Amalgamated Bank’s holdings in Cullinan Therapeutics were worth $30,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Deerfield Management Company L.P. Series C grew its stake in Cullinan Therapeutics by 188.1% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 3,280,237 shares of the company’s stock valued at $57,207,000 after buying an additional 2,141,706 shares during the last quarter. Marshall Wace LLP grew its position in shares of Cullinan Therapeutics by 2,416.9% in the second quarter. Marshall Wace LLP now owns 1,184,037 shares of the company’s stock valued at $20,650,000 after purchasing an additional 1,136,993 shares during the last quarter. Perceptive Advisors LLC acquired a new stake in shares of Cullinan Therapeutics in the second quarter valued at about $13,079,000. Lynx1 Capital Management LP bought a new position in shares of Cullinan Therapeutics in the second quarter worth about $6,581,000. Finally, Ensign Peak Advisors Inc acquired a new position in shares of Cullinan Therapeutics during the 2nd quarter worth about $2,595,000. Institutional investors and hedge funds own 86.31% of the company’s stock.

Insider Transactions at Cullinan Therapeutics

In other news, insider Jennifer Michaelson sold 8,000 shares of the stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $15.64, for a total value of $125,120.00. Following the completion of the transaction, the insider now directly owns 107,942 shares of the company’s stock, valued at approximately $1,688,212.88. This represents a 6.90 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 6.07% of the stock is owned by insiders.

Analysts Set New Price Targets

CGEM has been the topic of a number of research analyst reports. Wedbush reaffirmed an “outperform” rating and issued a $36.00 target price on shares of Cullinan Therapeutics in a report on Wednesday, September 18th. UBS Group started coverage on Cullinan Therapeutics in a research report on Thursday, October 24th. They issued a “buy” rating and a $30.00 price objective for the company. Finally, HC Wainwright reaffirmed a “buy” rating and set a $28.00 target price on shares of Cullinan Therapeutics in a research report on Wednesday, October 16th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Cullinan Therapeutics currently has a consensus rating of “Buy” and an average price target of $31.67.

Cullinan Therapeutics Trading Down 3.0 %

Shares of NASDAQ:CGEM opened at $13.45 on Tuesday. The firm has a market capitalization of $783.19 million, a PE ratio of -4.74 and a beta of -0.12. Cullinan Therapeutics, Inc. has a 1-year low of $7.64 and a 1-year high of $30.19. The business’s 50 day moving average is $16.44 and its 200-day moving average is $18.69.

Cullinan Therapeutics (NASDAQ:CGEM) last issued its earnings results on Thursday, November 7th. The company reported ($0.69) EPS for the quarter, topping the consensus estimate of ($0.78) by $0.09. On average, sell-side analysts predict that Cullinan Therapeutics, Inc. will post -3.12 EPS for the current year.

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.